Saxenda (Liraglutide)

Overview

Saxenda is a prescription injectable medication manufactured by Novo Nordisk that contains liraglutide, a GLP-1 receptor agonist. It was approved by the FDA in December 2014 specifically for chronic weight management in adults with a BMI of 30 or greater (obesity), or a BMI of 27 or greater (overweight) with at least one weight-related comorbidity such as high blood pressure, type 2 diabetes, or high cholesterol.

In 2020, Saxenda also received FDA approval for use in adolescents aged 12 and older with a body weight above 132 pounds (60 kg) and obesity, making it one of the few GLP-1 medications with pediatric approval. Saxenda uses the same active ingredient as Victoza (which is approved for type 2 diabetes), but at a higher dose of 3.0mg compared to Victoza's maximum of 1.8mg.

While newer GLP-1 medications like Wegovy and Zepbound have demonstrated greater average weight loss in clinical trials, Saxenda remains an important option due to its long track record, extensive safety data, and approval for younger patients. It is intended to be used alongside a reduced-calorie diet and increased physical activity.

How It Works

Saxenda works by mimicking the action of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone released in the gut after eating. GLP-1 plays a crucial role in regulating appetite and food intake by acting on receptors in the brain, particularly in the hypothalamus, the area responsible for hunger and satiety signals.

When you inject Saxenda, the liraglutide binds to GLP-1 receptors and activates them, leading to reduced appetite and increased feelings of fullness. This helps patients eat less and consume fewer calories without the intense hunger pangs that often derail traditional dieting efforts. Additionally, liraglutide slows gastric emptying, meaning food stays in the stomach longer, which further contributes to the sensation of being full.

Unlike its cousin semaglutide (found in Ozempic and Wegovy), liraglutide has a shorter half-life of approximately 13 hours, which is why Saxenda requires daily injections rather than weekly administration. While this is less convenient, it does mean the medication clears the body more quickly if side effects become problematic.

Dosing Schedule

Saxenda follows a gradual dose-escalation schedule over five weeks to help minimize gastrointestinal side effects. Patients begin with 0.6mg daily during the first week, then increase by 0.6mg each subsequent week until reaching the target maintenance dose of 3.0mg daily. This titration schedule is: Week 1 at 0.6mg, Week 2 at 1.2mg, Week 3 at 1.8mg, Week 4 at 2.4mg, and Week 5 onward at 3.0mg.

The injection is administered subcutaneously (under the skin) in the abdomen, thigh, or upper arm. Patients can inject at any time of day, with or without meals, though it is recommended to inject at approximately the same time each day for consistency. If a dose is missed, it should be skipped if more than 12 hours have passed since the usual injection time.

If patients cannot tolerate the dose increases, their healthcare provider may recommend slowing the escalation schedule by spending an additional week at each dose level. If a patient cannot tolerate the 3.0mg dose, the medication should be discontinued, as the full dose is needed for effective weight management results.

Weight Loss Results

In the landmark SCALE clinical trial program, which included over 5,000 participants, patients treated with Saxenda 3.0mg plus lifestyle modifications lost an average of approximately 8% of their body weight over 56 weeks. Roughly 63% of participants achieved at least 5% weight loss, and about 33% achieved 10% or more weight loss compared to their starting weight.

While these results are clinically meaningful and associated with improvements in blood pressure, cholesterol levels, and blood sugar control, they are more modest compared to newer GLP-1 medications. For context, Wegovy (semaglutide 2.4mg) has shown average weight loss of approximately 15%, and Zepbound (tirzepatide) has demonstrated weight loss of up to 22% in clinical trials.

It is important to note that individual results vary significantly. Some patients on Saxenda achieve substantial weight loss exceeding 15%, while others may see more modest results. Healthcare providers typically evaluate progress at 16 weeks; if a patient has not lost at least 4% of their body weight by that point, discontinuation is usually recommended as further weight loss is unlikely.

Side Effects

The most common side effects of Saxenda are gastrointestinal in nature. Nausea is the most frequently reported adverse event, affecting approximately 39% of patients in clinical trials, followed by diarrhea (21%), constipation (19%), vomiting (16%), and decreased appetite (10%). These side effects are typically most pronounced during the dose-escalation phase and tend to diminish over time as the body adjusts to the medication.

Other reported side effects include headache, dizziness, fatigue, abdominal pain, and injection site reactions. More serious but rare side effects include pancreatitis, gallbladder disease, increased heart rate, kidney problems, and allergic reactions. Saxenda carries a boxed warning regarding the risk of thyroid C-cell tumors, which were observed in animal studies, though this risk has not been confirmed in humans.

Patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use Saxenda. It is also contraindicated during pregnancy and should not be used with other GLP-1 receptor agonists or with insulin. Patients should report any symptoms of pancreatitis (severe abdominal pain) or allergic reactions to their healthcare provider immediately.

Cost and Insurance

The list price of Saxenda is approximately $1,300 to $1,500 per month without insurance, making it one of the more expensive weight management medications. Each Saxenda pen contains 18mg of liraglutide and, at the maintenance dose of 3.0mg daily, lasts approximately six days. Patients typically need five pens per month to maintain continuous treatment.

Insurance coverage for Saxenda varies widely. Many commercial insurance plans cover it when prescribed for obesity with documentation of BMI criteria and failed lifestyle interventions, though prior authorization is often required. Medicare Part D generally does not cover medications prescribed solely for weight loss, which can be a significant barrier for older adults. Novo Nordisk offers a savings card program that may reduce out-of-pocket costs for eligible commercially insured patients.

Patients exploring cost-saving options may want to discuss alternatives with their healthcare provider. Compounding pharmacies in some states offer compounded liraglutide at lower prices, though these are not FDA-approved products and carry additional risks. Generic liraglutide is not yet available in the United States, though this may change in the coming years as patent protections evolve.

Who Is Saxenda For?

Saxenda may be a good fit for adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related health condition. It is also approved for adolescents aged 12 and older with obesity, making it one of the few GLP-1 options available for younger patients. Patients who prefer a medication with a long track record and extensive safety data may favor Saxenda over newer alternatives.

Saxenda may be less ideal for patients who are uncomfortable with daily injections, as newer weekly options like Wegovy and Zepbound offer greater convenience and typically produce greater weight loss. Patients primarily seeking diabetes management should discuss Victoza or other diabetes-specific medications with their provider, as Saxenda is approved only for weight management.

Ultimately, the decision to use Saxenda should be made in consultation with a qualified healthcare provider who can evaluate your complete medical history, current medications, and personal health goals. Weight management is a long-term journey, and the best medication is one that aligns with your individual needs and that you can maintain consistently over time.